Blog

RSS Feed
Posted by Michael Wonder on 28 Nov 2018

Octapharma receives Swissmedic approval for fibryga to treat congenital and acquired fibrinogen deficiencies

26 November 2018 - Octapharma today announced that the Swiss Agency for Therapeutic Products, Swissmedic, granted marketing authorisation to its new ...

Read more →
Posted by Michael Wonder on 31 Oct 2016

Alprolix approved in Switzerland for the treatment of haemophilia B

28 October 2016 - Alprolix approved in Switzerland for the treatment of haemophilia B ...

Read more →
Posted by Michael Wonder on 27 Aug 2015

CSL Behring receives marketing authorisation for Respreeza in Europe

25 August 2015 - CSL Behring announced today that the European Commission (EC) has granted marketing authorization in all European Union ...

Read more →